Evans L, Rhodes A, Alhazzani W, Antonelli M. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Crit Care Med 2021;49(11):e1063–e1143. DOI: 10.1097/CCM.0000000000005337.
Boissier F, Aissaoui N. Septic cardiomyopathy: diagnosis and management. J Intensive Med 2022;2(1):8–16. DOI: 10.1016/j.jointm.2021.11.004.
L’Heureux M, Sternberg M, Brath L, Turlington J, Kashiouris MG. Sepsis-induced cardiomyopathy: a comprehensive review. Curr Cardiol Rep 2020;22(5):35. DOI: 10.1007/s11886-020-01277-2.
Bansal S, Varshney S, Shrivastava A. A prospective observational study to determine incidence and outcome of sepsis-induced cardiomyopathy in an intensive care unit. Indian J Crit Care Med 2021;26(6). DOI: 10.5005/jp-journals-10071-24204.
Jeong HS, Lee TH, Bang CH, Kim J-H, Hong SJ. Risk factors and outcomes of sepsis-induced myocardial dysfunction and stress induced cardiomyopathy in sepsis or septic shock: a comparative retrospective study. Medicine 2018;97(13):e0263. DOI: 10.1097/MD.0000000000010263.
Cunnion RE, Schaer GL, Parker MM, Natanson C, Parrillo JE. The coronary circulation in human septic shock. Circulation 1986;73(4): 637–644. DOI: 10.1161/01.cir.73.4.637.
Smart L, Bosio E, Macdonald SPJ, Dull R, Fatovich DM, Neil C, et al. Glycocalyx biomarker syndecan-1 is a stronger predictor of respiratory failure in patients with sepsis due to pneumonia, compared to endocan. J Crit Care 2018;47:93–98. DOI: 10.1016/j.jcrc.2018.06.015.
Stanzani G, Duchen MR, Singer M. The role of mitochondria in sepsis-induced cardiomyopathy. Biochim Biophys Acta Mol Basis Dis 2019;1865(4):759–773. DOI: 10.1016/j.bbadis.2018.10.011.
Hobai IA, Edgecomb J, LaBarge K, Colucci WS. Dysregulation of intracellular calcium transporters in animal models of sepsis- induced cardiomyopathy. Shock 2015;43(1):3–15. DOI: 10.1097/SHK.0000000000000261.
Bosch NA, Cohen DM, Walkey AJ. Risk factors for new-onset atrial fibrillation in patients with Sepsis: a systematic review and meta-analysis. Crit Care Med 2019;47(2):280–287. DOI: 10.1097/CCM.0000000000003560.
Adler A, Topaz G, Heller K, Zeltser D, Ohayon T, Rozovski U, et al. Fever-induced Brugada pattern: how common is it and what does it mean? Heart Rhythm 2013;10(9):1375–1382. DOI: 10.1016/j.hrthm.2013.07.030.
Repessé X, Charron C, Vieillard-Baron A. Evaluation of left ventricular systolic function revisited in septic shock. Crit Care 2013;17(4):164. DOI: 10.1186/cc12755.
Vallabhajosyula S, Kumar M, Pandompatam G, Sakhuja A, Kashyap R, Kashani K, et al. Prognostic impact of isolated right ventricular dysfunction in sepsis and septic shock: an 8-year historical cohort study. Ann Intensive Care 2017;7(1):94. DOI: 10.1186/s13613-017- 0319-9.
Landesberg G, Gilon D, Meroz Y, Georgieva M, Levin PD, Goodman S, et al. Diastolic dysfunction and mortality in severe sepsis and septic shock. Eur Heart J 2012;33(7):895–903. DOI: 10.1093/eurheartj/ehr351.
Sanfilippo F, Corredor C, Arcadipane A, Landesberg G, Vieillard- Baron A, Cecconi M, et al. Tissue Doppler assessment of diastolic function and relationship with mortality in critically ill septic patients: a systematic review and meta-analysis. Br J Anaesth 2017;119(4): 583–594. DOI: 10.1093/bja/aex254.
Charpentier J, Luyt C-E, Fulla Y, Vinsonneau C, Cariou A, Grabar S, et al. Brain natriuretic peptide: a marker of myocardial dysfunction and prognosis during severe sepsis. Crit Care Med 2004;32(3):660–665. DOI: 10.1097/01.ccm.0000114827.93410.d8.
Hernandez G, Bruhn A, Luengo C, Regueira T, Kattan E, Fuentealba A, et al. Effects of dobutamine on systemic, regional and microcirculatory perfusion parameters in septic shock: a randomized, placebo-controlled, double-blind, crossover study. Intensive Care Med 2013;39(8):1435–1443. DOI: 10.1007/s00134-013-2982-0.
Gordon AC, Perkins GD, Singer M, McAuley DF, Orme RML, Santhakumaran S, et al. Levosimendan for the prevention of acute organ dysfunction in sepsis. N Engl J Med 2016;375(17):1638–1648. DOI: 10.1056/NEJMoa1609409.
Kakihana Y, Nishida O, Taniguchi T, Okajima M, Morimatsu H, Ogura H, et al. Efficacy and safety of landiolol, an ultra-short-acting β1-selective antagonist, for treatment of sepsis-related tachyarrhythmia (J-Land 3S): a multicentre, open-label, randomised controlled trial. Lancet Respir Med 2020;8(9):863–872. DOI: 10.1016/S2213-2600(20)30037-0.
